Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

MathWorks, a leading developer of mathematical simulation and computing software, revealed that a ransomware gang stole the data of over 10,000 people after breaching its network in April. The company ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

Section 1. Policy and Purpose. My Administration has inaugurated a golden age for American manufacturing and technological dominance. We will pursue bold, large-scale industrial plans to vault the ...

NEW YORK--(BUSINESS WIRE)--KBRA releases research examining the differences between asset-backed securities (ABS) and commercial mortgage-backed securities (CMBS) for data center transactions, ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

Structure Therapeutics' GSBR-1290 showed a placebo-adjusted mean weight loss of 6.2% at 12 weeks, suggesting potential despite initial underwhelming results. Comparatively, Eli Lilly’s orforglipron ...